Patents by Inventor Dwight Stickney
Dwight Stickney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130338125Abstract: The invention provides and describes solid state 17?-ethynyl-5?-androstane-3?,17?-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-5?-androstane-3?,17?-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17?-ethynyl-5?-androstane-3?,17?-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-5?-androstane-3?,17?-diol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: June 17, 2013Publication date: December 19, 2013Inventors: Steven K. White, Dwight Stickney
-
Patent number: 8217025Abstract: The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol and 4?-fluoro-17?-ethynylandrost-5-ene-3?,17?-triol-7-one.Type: GrantFiled: November 19, 2007Date of Patent: July 10, 2012Assignee: Harbor Therapeutics, Inc.Inventors: Jaime Flores-Riveros, James M. Frincke, Christopher Reading, Dwight Stickney, Clarence N. Ahlem
-
Publication number: 20100227841Abstract: The invention provides 17?-ethynylandrost-5-ene-3?,7?,17?-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 ?U/mL.Type: ApplicationFiled: March 25, 2010Publication date: September 9, 2010Applicant: Harbor BioSciencs, Inc.Inventors: Dwight Stickney, Christopher L. Reading, James M. Frincke
-
Publication number: 20100222315Abstract: The invention provides 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (?30.5, ?31 or ?32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will generally have a fasting insulin level of at least 4 ?U/mL or another characteristic as described herein.Type: ApplicationFiled: March 25, 2010Publication date: September 2, 2010Applicant: Harbor BioSciencs, Inc.Inventors: Christopher L. Reading, James M. Frincke, Dwight Stickney, Jaime Flores-Riveros
-
Publication number: 20100075937Abstract: The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 ?U/mL or at least 6 ?U/mL and optionally (i) a serum MCP1 level of at least about 400 pg/mL or at least about 500 pg/mL. The treatment method includes administering 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol and optionally another compound such as metformin or glyburide. Specific embodiments include use of 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol for the treatment of hypercholesterolemia in a patient and a BMI of at least 28 or 29 and optionally hyperglycemia. In these embodiments, the patient will most preferably have a fasting insulin level of at least 4 ?U/mL or at least 5 ?U/mL.Type: ApplicationFiled: September 24, 2009Publication date: March 25, 2010Applicant: Hollis-Eden Pharmaceuticals, Inc.Inventors: Jaime Flores-Riveros, James M. Frincke, Christopher L. Reading, Dwight Stickney
-
Publication number: 20090291932Abstract: The invention provides and describes solid state 17?-ethynyl-5?-androstane-3?,17?-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-5?-androstane-3?,17?-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17?-ethynyl-5?-androstane-3?,17?-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-5?-androstane-3?,17?-diol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: February 12, 2009Publication date: November 26, 2009Applicant: HollisEden Pharmaceuticals, INC.Inventors: Steven K. White, Dwight Stickney, Erin Olson, Keith Richard Lorimer, Brenton Skylar Wolfe
-
Publication number: 20080221074Abstract: The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol and 4?-fluoro-17?-ethynylandrost-5-ene-3?,17?-triol-7-one.Type: ApplicationFiled: November 17, 2007Publication date: September 11, 2008Inventors: Jaime Flores-Riveros, James M. Frincke, Christopher Reading, Dwight Stickney, Clarence Ahlem
-
Publication number: 20080146532Abstract: The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4?-fluoro-17?-ethynylandrost-5-ene-3?, 7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol and 4?-fluoro-17?-ethynylandrost-5-ene-3?,17?-triol-7-one.Type: ApplicationFiled: November 19, 2007Publication date: June 19, 2008Inventors: Jaime Flores-Riveros, James M. Frincke, Christopher Reading, Dwight Stickney, Clarence N. Ahlem
-
Publication number: 20080015174Abstract: The invention relates to the use of compounds to treat a number of conditions, such as a pre-diabetes condition, type 1 diabetes, type 2 diabetes, hyperglycemia, insulin resistance and glucose intolerance. Compounds that can be used in one or more of the treatment methods include 3?,7?,16?,17?-tetrahydroxyandrost-5-ene, 3?,7?,16?,17?-tetrahydroxyandrost-5-ene, 3?,7?,16?,17?-tetrahydroxyandrost-5-ene, 3?,16?,17?-trihydroxyandrost-5-ene-7-one, 3?,7?,17?-trihydroxy-17?-ethynylandrost-5-ene, 3?,17?-dihydroxy-17?-ethynylandrost-5-ene-7-one and 3?,7?,17?-trihydroxy-17?-ethynylandrost-5-ene.Type: ApplicationFiled: April 4, 2007Publication date: January 17, 2008Inventors: Christopher Reading, James Frincke, Clarence Ahlem, Dwight Stickney
-
Publication number: 20070275937Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: February 12, 2007Publication date: November 29, 2007Inventors: Christopher Reading, Clarence Ahlem, Dominick Auci, Charles Dowding, James Frincke, Mei Li, Theodore Page, Dwight Stickney, Richard Trauger, Steven White
-
Publication number: 20070275938Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: February 12, 2007Publication date: November 29, 2007Inventors: Christopher Reading, Clarence Ahlem, Dominick Auci, Charles Dowding, James Frincke, Mei Li, Theodore Page, Dwight Stickney, Richard Trauger, Steven White
-
Publication number: 20070265236Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: October 16, 2006Publication date: November 15, 2007Inventors: Christopher Reading, Clarence Ahlem, Dominick Auci, Charles Dowding, James Frincke, Mei Li, Theodore Page, Dwight Stickney, Richard Trauger, Steven White
-
Publication number: 20070213309Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: October 16, 2006Publication date: September 13, 2007Inventors: Christopher Reading, Clarence Ahlem, Dominick Auci, Charles Dowding, James Frincke, Mei Li, Theodore Page, Dwight Stickney, Richard Trauger, Steven White
-
Publication number: 20070077203Abstract: The invention provides a method to analyze an effect of a biological insult such as exposure to ionizing radiation comprising (a) exposing one or more groups of subjects to a biological insult of at least about an LD10 to obtain one or more groups of exposed subjects; and (b) measuring one, two, three or more surrogate markers in one or more of the groups of exposed subjects, wherein one, two, three or more of the surrogate markers correlate with death at a P?0.1.Type: ApplicationFiled: March 24, 2006Publication date: April 5, 2007Inventors: Armando Garsd, James Frincke, Dwight Stickney
-
Publication number: 20060088473Abstract: The invention includes a method to identify a method to enhance survival of a subject such as a non-human primate that has been exposed to a biological insult such as an ionizing radiation dose of about LD30/30 or about LD50/30 by treating the exposed subject with a test compound an optionally comparing the results to that obtained using control subjects that had been treated with 3?,17?-dihydroxyandrost-5-ene or other disclosed compounds.Type: ApplicationFiled: October 3, 2005Publication date: April 27, 2006Inventors: Charles Dowding, James Frincke, Armando Garsd, Christopher Reading, Dwight Stickney, Clarence Ahlem
-
Publication number: 20060079492Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3?-yl)-?-D-glucopyranosiduronate, 16?,3?-dihydroxy-5?-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.Type: ApplicationFiled: September 23, 2005Publication date: April 13, 2006Inventors: Clarence Ahlem, Christopher Reading, James Frincke, Dwight Stickney, Henry Lardy, Padma Marwah, Ashok Marwah, Patrick Prendergast
-
Publication number: 20060073099Abstract: The invention includes a method to identify a method to enhance survival of a subject that has been exposed to a biological insult such as an ionizing radiation dose of LD50/30 by treating the exposed subject with a test compound an optically comparing the results to that obtained using control subjects that had been treated with 3?,17?-dihydroxyandrost-5-ene or other disclosed compounds.Type: ApplicationFiled: September 30, 2005Publication date: April 6, 2006Inventors: James Frincke, Charles Dowding, Armando Garsd, Christopher Reading, Dwight Stickney, Clarence Ahlem
-
Publication number: 20050101581Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: December 5, 2003Publication date: May 12, 2005Inventors: Christopher Reading, Clarence Ahlem, Dominick Auci, Charles Dowding, James Frincke, Mei Li, Theodore Page, Dwight Stickney, Richard Trauger, Steven White
-
Publication number: 20030083231Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.Type: ApplicationFiled: March 1, 2002Publication date: May 1, 2003Inventors: Clarence N. Ahlem, Christopher Reading, James Frincke, Dwight Stickney, Henry A. Lardy, Padma Marwah, Ashok Marwah, Patrick T. Prendergast